197 related articles for article (PubMed ID: 27447545)
1. Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma.
Pérez-Blanco JS; Santos-Buelga D; Fernández de Gatta MD; Hernández-Rivas JM; Martín A; García MJ
Br J Clin Pharmacol; 2016 Dec; 82(6):1517-1527. PubMed ID: 27447545
[TBL] [Abstract][Full Text] [Related]
2. Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: Estimation of doxorubicin hepatic extraction ratio.
Pippa LF; Oliveira ML; Rocha A; de Andrade JM; Lanchote VL
J Pharm Biomed Anal; 2020 Jun; 185():113231. PubMed ID: 32163849
[TBL] [Abstract][Full Text] [Related]
3. Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma.
Toffoli G; Corona G; Cattarossi G; Boiocchi M; Di Gennaro G; Tirelli U; Vaccher E
Ann Oncol; 2004 Dec; 15(12):1805-9. PubMed ID: 15550586
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin area under the curve is an important predictor of neutropenia in dogs with naturally occurring cancers.
Wittenburg LA; Weishaar K; Ramirez D; Gustafson DL
Vet Comp Oncol; 2019 Jun; 17(2):147-154. PubMed ID: 30638304
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of doxorubicin and its active metabolite in patients with normal renal function and in patients on hemodialysis.
Yoshida H; Goto M; Honda A; Nabeshima T; Kumazawa T; Inagaki J; Yamanaka N; Ota K
Cancer Chemother Pharmacol; 1994; 33(6):450-4. PubMed ID: 8137454
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and cardiotoxicity of doxorubicin and its secondary alcohol metabolite in rats.
Zeng X; Cai H; Yang J; Qiu H; Cheng Y; Liu M
Biomed Pharmacother; 2019 Aug; 116():108964. PubMed ID: 31102935
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic herb-drug interactions between Aidi injection and doxorubicin in rats with diethylnitrosamine-induced hepatocellular carcinoma.
Lu Y; Pan J; Zhu X; Zhang S; Liu C; Sun J; Li Y; Chen S; Huang J; Cao C; Wang Y; Li Y; Liu T
BMC Pharmacol Toxicol; 2021 Sep; 22(1):48. PubMed ID: 34488896
[TBL] [Abstract][Full Text] [Related]
8. Investigation of hepatobiliary disposition of doxorubicin following intrahepatic delivery of different dosage forms.
Lilienberg E; Ebeling Barbier C; Nyman R; Hedeland M; Bondesson U; Axén N; Lennernäs H
Mol Pharm; 2014 Jan; 11(1):131-44. PubMed ID: 24171458
[TBL] [Abstract][Full Text] [Related]
9. The effects of lipiodol and cyclosporin A on the hepatobiliary disposition of doxorubicin in pigs.
Dubbelboer IR; Lilienberg E; Hedeland M; Bondesson U; Piquette-Miller M; Sjögren E; Lennernäs H
Mol Pharm; 2014 Apr; 11(4):1301-13. PubMed ID: 24558959
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
[TBL] [Abstract][Full Text] [Related]
11. Pharmacology and clinical toxicity of 4'-iodo-4'-deoxydoxorubicin: an example of successful application of pharmacokinetics to dose escalation in phase I trials.
Gianni L; Viganò L; Surbone A; Ballinari D; Casali P; Tarella C; Collins JM; Bonadonna G
J Natl Cancer Inst; 1990 Mar; 82(6):469-77. PubMed ID: 2313718
[TBL] [Abstract][Full Text] [Related]
12. Effect of tamoxifen on the pharmacokinetics of doxorubicin in patients with non-Hodgkin's lymphoma.
El-Yazigi A; Berry J; Ezzat A; Wahab FA
Ther Drug Monit; 1997 Dec; 19(6):632-6. PubMed ID: 9421103
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG.
Joerger M; Huitema AD; Richel DJ; Dittrich C; Pavlidis N; Briasoulis E; Vermorken JB; Strocchi E; Martoni A; Sorio R; Sleeboom HP; Izquierdo MA; Jodrell DI; Féty R; de Bruijn E; Hempel G; Karlsson M; Tranchand B; Schrijvers AH; Twelves C; Beijnen JH; Schellens JH;
Clin Pharmacokinet; 2007; 46(12):1051-68. PubMed ID: 18027989
[TBL] [Abstract][Full Text] [Related]
14. Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP.
Baudry E; Huguet S; Couderc AL; Chaibi P; Bret F; Verny C; Weill S; Madar O; Urien S; Rezai K
Cancer Chemother Pharmacol; 2019 Apr; 83(4):775-785. PubMed ID: 30689002
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin and doxorubicinol plasma concentrations and excretion in parotid saliva.
Bressolle F; Jacquet JM; Galtier M; Jourdan J; Donadio D; Rossi JF
Cancer Chemother Pharmacol; 1992; 30(3):215-8. PubMed ID: 1628370
[TBL] [Abstract][Full Text] [Related]
16. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505.
Itoh K; Ohtsu T; Fukuda H; Sasaki Y; Ogura M; Morishima Y; Chou T; Aikawa K; Uike N; Mizorogi F; Ohno T; Ikeda S; Sai T; Taniwaki M; Kawano F; Niimi M; Hotta T; Shimoyama M; Tobinai K;
Ann Oncol; 2002 Sep; 13(9):1347-55. PubMed ID: 12196359
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetic modelling of doxorubicin and doxorubicinol in children with cancer: is there a relationship with cardiac troponin profiles?
Kunarajah K; Hennig S; Norris RLG; Lobb M; Charles BG; Pinkerton R; Moore AS
Cancer Chemother Pharmacol; 2017 Jul; 80(1):15-25. PubMed ID: 28444427
[TBL] [Abstract][Full Text] [Related]
19. Toxicokinetics of the active doxorubicin metabolite, doxorubicinol, in sulphur-crested cockatoos (Cacatua galerita).
Gilbert CM; Filippich LJ; McGeary RP; Charles BG
Res Vet Sci; 2007 Aug; 83(1):123-9. PubMed ID: 17197005
[TBL] [Abstract][Full Text] [Related]
20. Doxorubicin metabolism and toxicity in human myocardium: role of cytoplasmic deglycosidation and carbonyl reduction.
Licata S; Saponiero A; Mordente A; Minotti G
Chem Res Toxicol; 2000 May; 13(5):414-20. PubMed ID: 10813659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
